Clopidogrel Bisulfate Tablet, Film Coated
Product Images NDC 43598-121

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Clopidogrel Bisulfate (NDC 43598-121). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Dr.reddy's Laboratories Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Carton (Carton)

This is a description of clopidogrel tablets containing 300 mg of clopidogrel base. The tablets are film-coated and come in a package of 30 tablets. The storage instructions are to keep the tablets at 25°C (77°F) with excursions permitted to 15-30°C (59-86°F). The tablets are distributed by Dr. Reddy's Laboratories Inc. and the expiration date is R02/2025. It is recommended to follow the Medication Guide provided with each patient's prescription.*

FDA Label Image

Container1 (Container1)

FDA Label Image

Container2 (Container2)

FDA Label Image

Figure1 (Figure1)

This text provides information about the effect of co-administering different proton pump inhibitors (PPIs) on the area under the curve (AUC) of the active metabolite. The AUC is presented as mean values and 90% confidence intervals for Dexlansoprazole (60 mg), Lansoprazole (30 mg), Pantoprazole (80 mg), and Omeprazole (80 mg). The values for each PPI are listed as follows: Dexlansoprazole - T, Lansoprazole - T, Pantoprazole - T, Omeprazole - T. The data seems to be related to a study or pharmacokinetic analysis of these PPIs and their impact on active metabolite AUC.*

FDA Label Image

Figure2 (Figure2)

This text provides information on the event rate of Clopidogrel in combination with aspirin over a 12-month follow-up period. Other standard therapies were also utilized as needed.*

FDA Label Image

Figure3 (Figure3)

FDA Label Image

Figure4 (Figure4)

This text provides information on the comparison of mortality rates between Placebo and Clopidogrel treatments, with 1845 deaths (8.1%) in the Placebo group and 1726 deaths (7.5%) in the Clopidogrel group. The analysis shows a 7% proportional risk reduction with a p-value of 0.03. The data is presented in the context of days since randomization (up to 28 days).*

FDA Label Image

Figure5 (Figure5)

This text appears to be a comparison between two groups, one taking a placebo and the other taking Clopidogrel. The study evaluated the occurrence of death, reinfarction, or stroke before discharge from the hospital. The placebo group had 2310 events (10.1%), while the Clopidogrel group had 2121 events (9%), indicating a 9% proportional risk reduction with Clopidogrel (p=0.002). The evaluation was conducted over a period of up to 28 days since randomization.*

FDA Label Image

Figure6 (Figure6)

FDA Label Image

Figure7 (Figure7)

FDA Label Image

Figure8 (Figure8)

FDA Label Image

Structure (Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.